37 results about "Cmv infections" patented technology

Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit human CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.

The invention discloses a method for synchronously detecting three kinds of viruses on tobacco through triple one-step method RT-PCR (Reverse Transcription Polymerase Chain Reaction). The method is characterized by being used for synchronously detecting TMV (Tobacco Mosaic Virus), PVY (Potato Virus Y) and CMV (Cucumber Mosaic Virus), the method comprises the following steps of screening and comparing conservation areas in a virus gene group, artificially screening and synthesizing specificity primers suitable for composite RT-PCR of three kinds of virus diseases; analyzing to obtain TMV, PVY and CMV infection tobacco leaf samples; and integrating enzymes and a buffer solution required by a reverse transcription and a PCR (Polymerase Chain Reaction), and establishing a method for compositely detecting the TMV, PCY and CMV infection of tobacco leaves based on one-step method RT-PCR through optimization of reaction conditions. The triple one-step method RT-PCR utilized by the invention has the advantages of simple and convenient operation, time and labor saving, reliable result and low cost; simultaneously, the probability of cross-contamination of samples in an operation process canbe effectively reduced, and the monitoring on the TMV, PVY and CMV in tobacco agricultural production has wide application prospect.

This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the production of both DNA and protein vaccines. Therefore, the invention provides proteins and DNAS, as well as vaccines comprising the proteins and DNAs, including cellular vaccines and vectors. Other embodiments of the invention relate to methods of enhancing immune response and vaccinating against CMV, including gene therapy methods and vectors.

Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.

The invention provides an immunogen composition containing polypeptide derived from cytomegalovirus (CMV) and a use method thereof. The composition comprises (a) at least one of CMV pp65 and polypeptide derived from CMV IE-1 polypeptide; and (b) polypeptide selected from groups formed by polypeptides derived from CMV VGLB, CMV VPAP and CMV p100 polypeptides, and the combination thereof. The immunogen composition of the invention can effectively activate CMV resistant immunoreaction after confirmation. Live virus, cells infected by CMV, and full-length CMV cells are not used in a polypeptide library so that no infection, mmunosuppression action, immunologic tolerance and the like are caused.

The invention discloses a chemiluminescence immunoassay analysis diagnosing test kit and a preparing method thereof for detecting cytomegalovirus IgG antibody. The test kit includes positive and negative reference substance, solid-phase carrier, labeled antigen, enzyme-labeled antibody, chemiluminescence zymolyte liquid and condensed washing liquid. The test kit has great significance in screening diagnosis and monitoring for pre-pregnancy and early-pregnancy infection of childbearing women as well as CMV infection diagnosis of high risk group (such as tumour, organ transplanting, HIV and the like ).

The present invention relates to methods of inducing an immune response to cytomegalovirus (CMV) using a genetically modified CMV that is conditionally replication defective. The methods of the invention can be used to treat and / or prevent primary CMV infection, infection due to reactivation of a latent CMV and a super-infection of a different strain of CMV that had been previously encountered. The present invention also relates to a replication defective CMV which has been recombinantly altered to allow for external control of viral replication. Compositions comprising the replication defective CMV are also encompassed by the present invention.

The invention provides an expansion culture method of CD8 T cells. The CD8 T cells are subjected to induced expansion culture in the presence of the following substances: K3EC cells and a peptide-fragment overlapping library of a target antigen; and the K3EC cells are K562 engineering cells expressing CD2 ligands CD58, NKG2D ligands MICA / B and CD137 ligands CD137L and are used for providing costimulatory receptor second signals activating the CD8 T cells, and the peptide-fragment overlapping library of the target antigen is used for providing T cell receptor (TCR) first signals activating theCD8 T cells. According to the method, quick and efficient expansion of the antigen (CMV-pp65) specific CD8 T cells; and the CD8 T cells obtained through expansion have high clinical application valuein prevention and treatment of CMV infection and treatment of CMV-related cancers.

A method of designing a new anti-CMV drug is disclosed. In one embodiment, the invention comprises (a) analyzing the binding of glycoprotein O to a glycoprotein O receptor and (b) designing a candidate drug that would competitively interfere with glycoprotein O binding to glycoprotein O receptor and (c) showing that the candidate drug competitively inhibits glycoprotein O binding to glycoprotein O receptor. A method of screening anti-CMV drugs, a vaccine effective to diminish CMV infection, and a method of diminishing CMV infection are also disclosed.

Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.

The invention relates to a kit and a method for detecting CMV infection in a trace biological sample of an eye, and relates to a molecular detection technology for eye viral infections, in particularto a method for extracting DNA from the trace biological sample, wherein the trace biological sample refers to a liquid sample with a volume not exceeding 10mu l-200mu l or a solid sample with a volume not exceeding 1mm<3>. By use of the extracted DNA as a PCR detection template, the eye viral infections can be detected with an accuracy of 80% or more, and the method provides a reliable basis forsubsequent appropriate treatment methods and reduces the blindness of the treatment methods.

The invention provides compositions and methods useful for early detection of congenital CMV infection, predicting the likelihood and severity of congenital CMV disease, and monitoring the efficacy of therapeutic approaches. Compositions of the present invention include biomarkers that are differentially expressed in CMV-infected mothers and fetuses compared to uninfected individuals.

The present invention relates to the field of cytomegalovirus (CMV) infection. In particular the present invention relates to highly specific immunotoxins useful in treating diseases related to CMV infection. CMV encodes chemokine receptors that undergo constitutive internalization. Thus CMV infected cells can be targeted specifically with immunotoxins with high affinity to CMV encoded constitutively internalizing receptors. This will ensure efficient uptake of the immunotoxin by the CMV infected cell, and thereby ensure the death of the infected cell with a minimum of unwanted toxicity and side effects. Furthermore, the invention relates to a way of inhibiting CMV replication and / or growth by using immunotoxins by targeting constitutively internalizing CMV encoded receptors.

Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.

In one embodiment, an expression system for expressing a UL128 complex is provided herein. The expression system may include a bacterial artificial chromosome (BAC) construct, wherein the BAC construct comprises a viral vector inserted with a set of DNA sequences that encode a UL128 complex. In another embodiment, a vaccine composition for preventing HCMV infection is provided. The vaccine composition may include a viral or bacterial vector capable of expressing a UL128 complex and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof or additional vector expressing a protein adjuvant. The viral vector may be an MVA and the UL128 complex includes five HCMV proteins or antigenic fragments thereof: UL128, UL130, UL131A, gL, and gH. In some embodiments, the viral vector is further inserted with one or more additional DNA sequences that encode one or more additional HCMVHCMV proteins or antigenic fragments thereof such as pp65, gB or both, or such as gM / gN or gO.

Provided herein are immunogenic polypeptides, compositions, and methods related to the development of CMV-specific prophylactic and / or therapeutic immunotherapy based on T cell epitopes (e.g., CMV epitopes) that are recognized by cytotoxic T cells (CTLs) and can be employed in the prevention and / or treatment of CMV infection, reactivation, and / or disease (e.g., CMV-associated end organ disease), especially in solid organ transplant recipients.

The present invention relates to the field of cytomegalovirus (CMV) infection. In particular the present invention relates to highly specific immunotoxins useful in treating diseases related to CMV infection. CMV encodes chemokine receptors that undergo constitutive internalization. Thus CMV infected cells can be targeted specifically with immunotoxins with high affinity to CMV encoded constitutively internalizing receptors. This will ensure efficient uptake of the immunotoxin by the CMV infected cell, and thereby ensure the death of the infected cell with a minimum of unwanted toxicity and side effects. Furthermore, the invention relates to a way of inhibiting CMV replication and / or growth by using immunotoxins by targeting constitutively internalizing CMV encoded receptors.

The present invention provides novel inhibitors of inflammation and methods for treating inflammation by using these inhibitors. More specifically, the present invention provides transcription inhibitors, i.e., peptide fragments derived from internal regions of the Cytomegalovirus (CMV) IE2 protein that can inhibit production of inflammatory cytokines, e.g., Interleukin 1 beta(IFN-1β) and the methods for treating inflammatory diseases and CMV infection and related disorders, by using the IE2 fragments. An pharmaceutical composition comprising the transcription inhibitor are also provided.

The invention relates to a RNA interference sequence targeting a cucumber mosaic virus, an expression vector thereof and application. The cucumber mosaic virus targeted RNA interference sequence is double-stranded RNA, is composed of a sense strand and an antisense strand, and is an interference sequence GT1 of a GT1 gene specifically targeting CMV-1a protein, or an interference sequence GT2 of a GT2 gene specifically targeting CMV-1a protein, or an interference sequence GT3 of a GT3 gene specifically targeting CMV-2a protein, or an interference sequence GT4 of a GT4 gene specifically targeting CMV-2a protein, or an interference sequence GT5 of a GT5 gene specifically targeting CMV-CP protein, or an interference sequence GT16 of a GT6 gene specifically targeting CMV-MP protein. The double-stranded RNA interference sequence is used for degrading target messenger RNA, reducing expression of target protein, effectively silencing CMV genes and controlling CMV infection, and has the characteristic of environmental friendliness and high commercial application value.

Described herein are materials and methods for stratifying risk for reactivation of a latent viral infection, such as CMV infection. The methods are particularly useful for immune compromised subjects. Also described herein are interventions, including therapeutic, prophylactic, and monitoring interventions, for subjects determined to be at elevated risk.

The method for simultaneously detecting three viruses on tobacco by triple one-step RT-PCR is characterized in that: it is a method for simultaneously detecting tobacco common mosaic virus, potato virus Y and cucumber mosaic virus, and the method includes screening and comparison of conserved virus genomes Region, manual screening and synthesis of compound RT-PCR specific primers suitable for three viral diseases; analysis of TMV, PVY, CMV infected tobacco leaf samples; integration of enzymes and buffers required for reverse transcription and PCR reactions, through optimization of reaction conditions, To establish a method based on one-step RT-PCR combined detection of TMV, PVY and CMV infection in tobacco leaves. The triple one-step RT-PCR reaction adopted in the present invention has the advantages of simple and convenient operation, time-saving and labor-saving, reliable results, and low cost, and can effectively reduce the possibility of cross-contamination of samples during the operation process. , PVY, CMV monitoring and monitoring has a wide range of application prospects.

The present invention provides a method for expanding and culturing CD8 T cells, that is, in the presence of the following substances, inducing, expanding and culturing CD8 T cells: K3EC cells; the K3EC cells express CD2 ligand CD58 and NKG2D ligand MICA / B K562 engineered cells with CD137 ligand CD137L are used to provide the second signal of co-stimulatory receptors to activate CD8 T cells; peptide overlapping libraries of target antigens are used to provide TCR first signals to activate CD8 T cells. This method realizes the rapid and efficient expansion of antigen (CMV-pp65)-specific CD8 T cells; the CD8 T cells obtained through the expansion have high clinical application value in the prevention and treatment of CMV infection and the treatment of CMV-related cancers.

The present invention provides novel inhibitors of inflammation and methods for treating inflammation by using these inhibitors. More specifically, the present invention provides transcription inhibitors, i.e., peptide fragments derived from internal regions of the Cytomegalovirus (CMV) IE2 protein that can inhibit production of inflammatory cytokines, e.g., Interleukin 1 beta (IFN-l beta) and the methods for treating inflammatory diseases and CMV infection and related disorders, by using the IE2 fragments. An pharmaceutical composition comprising the transcription inhibitor are also provided.

The present disclosure provides a method for inhibiting cytomegalovirus (CMV) replication in a cell infected with CMV, the method comprising contacting the cell with a bisbenzimidazole compound. The present disclosure provides a method of treating a CMV infection in an individual, the method comprising administering to the individual an effective amount of a bisbenzimidazole compound.

The present disclosure provides a method for inhibiting cytomegalovirus (CMV) replication in a cell infected with CMV, the method comprising contacting the cell with a bisbenzimidazole compound. The present disclosure provides a method of treating a CMV infection in an individual, the method comprising administering to the individual an effective amount of a bisbenzimidazole compound.

The present invention relates the field of CMV and CMV related diseases. Using a powerful rat model of CMV infection of the embryonic brain, the inventors have looked for the existence of postnatal neurological and neurosensory manifestations, and have tested whether the early pharmacological targeting of microglia during pregnancy impacts on postnatal phenotypes. Particularly, the inventors tested the clodronate and the doxycycline and showed that these compounds improve the postnatal outcome of the baby. Thus, the invention relates to a compound which modifies the microglia for use in the treatment of CMV related diseases in a subject in need thereof.

The invention relates to a kit and a method for detecting CMV infection in a trace biological sample of an eye, and relates to a molecular detection technology for eye viral infections, in particularto a method for extracting DNA from the trace biological sample, wherein the trace biological sample refers to a liquid sample with a volume not exceeding 10mu l-200mu l or a solid sample with a volume not exceeding 1mm<3>. By use of the extracted DNA as a PCR detection template, the eye viral infections can be detected with an accuracy of 80% or more, and the method provides a reliable basis forsubsequent appropriate treatment methods and reduces the blindness of the treatment methods.

In one embodiment, an expression system for expressing a UL128 complex is provided herein. The expression system may include a bacterial artificial chromosome (BAC) construct, wherein the BAC construct comprises a viral vector inserted with a set of DNA sequences that encode a UL128 complex. In another embodiment, a vaccine composition for preventing HCMV infection is provided. The vaccine composition may include a viral or bacterial vector capable of expressing a UL128 complex and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof or additional vector expressing a protein adjuvant. The viral vector may be an MVA and the UL128 complex includes five HCMV proteins or antigenic fragments thereof: UL128, UL130, UL131A, gL, and gH. In some embodiments, the viral vector is further inserted with one or more additional DNA sequences that encode one or more additional HCMVHCMV proteins or antigenic fragments thereof such as pp65, gB or both, or such as gM / gN or gO.